Claritev Corp

Claritev Corp(CTEV)股票分析

$23.500

0.000 (0.00%)收盘时

Loading chart…
最高
23.925
开盘
23.460
成交量加权均价
23.56
成交量
690.79K
市值
—
最低
23.260
成交额
16.28M
企业价值/息税折旧摊销前利润(TTM)
8.58

Claritev Corp, formerly MultiPlan Corporation, is a healthcare technology, data and insights company. The Company’s services include analytics-based services, data & decision science services, network-based services, payment and revenue integrity, end-to-end surprise billing service, and Claritev payments. The Company uses its analytics-based services to price surprise bills and leverages reimbursement data from millions of claims repriced through these services and accepted by providers to assist in negotiations and calculate offers for arbitration when necessary. It uses its payment integrity services on its network claims. The Company’s payment integrity offers advanced code editing, clinical negotiation, itemized bill review, coordination of benefits, subrogation, data mining, Medicare secondary payer validation, and end stage renal disease validation. It provides solutions for the commercial market, government healthcare plans, and property and casualty healthcare payors.

AI 分析 of Claritev Corp (CTEV)

买入

Claritev Corporation (CTEV) appears to be a good buy right now. The current price is $23.50, which is significantly lower than the average analyst price target of $40, indicating a potential upside of over 70%. Additionally, the company has shown a positive trend with a 6.24% increase over the past five days and a narrowed quarterly loss of $59.23 million, down from $62.64 million year-over-year, reflecting improved operational efficiency. However, a key risk is the high debt-to-equity ratio, which stands at 0%, indicating potential financial instability if market conditions worsen.

估值指标

Claritev Corp(CTEV)当前预期市盈率为 3.42,5 年平均预期市盈率为 -0.65。

预期市盈率

合理
5 年均值 P/E
-0.65
当前P/E
3.42
高估
3.43
低估
-4.74

预期 EV/EBITDA

低估
5 年均值 EV/EBITDA
9.23
当前EV/EBITDA
8.58
高估
9.88
低估
8.58

预期市销率

合理
5 年均值 P/S
0.58
当前P/S
0.37
高估
0.84
低估
0.31

Alphio AI 对 CTEV 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%CTEV

$27.94

情景价格

基

基准

基准 · 50%CTEV

$26.34

情景价格

悲

悲观

悲观 · 25%CTEV

$21.83

情景价格

持有 CTEV 的大户

T

The Public Investment Fund of The Kingdom of Saudi Arabia

+ 持有CTEV

-10.59%

3个月收益率

H

Hellman & Friedman LLC

+ 持有CTEVMDLN

-11.20%

3个月收益率

事件时间线

2026-09-22 (ET)

09:30:00

Claritev Selected to Support World Trade Center Health Program

2026-09-15 (ET)

09:30:00

Claritev Appoints Ben Letham as Director

2026-08-07 (ET)

05:30:00

Company Raises FY26 Adjusted EBITDA Outlook to $620M

05:30:00

Claritev Q2 Revenue Reaches $257.48M, Exceeds Expectations

2026-07-14 (ET)

13:30:00

Justice Department Expands Antitrust Investigation into Claritev

资讯

CTEV 常见问题 —— 由 Alphio AI 解答

Claritev Corp, formerly MultiPlan Corporation, is a healthcare technology, data and insights company. The Company’s services include analytics-based services, data & decision science services, network-based services, payment and revenue integrity, end-to-end surprise billing service, and Claritev payments. The Company uses its analytics-based services to price surprise bills and leverages reimbursement data from millions of claims repriced through these services and accepted by providers to assist in negotiations and calculate offers for arbitration when necessary. It uses its payment integrity services on its network claims. The Company’s payment integrity offers advanced code editing, clinical negotiation, itemized bill review, coordination of benefits, subrogation, data mining, Medicare secondary payer validation, and end stage renal disease validation. It provides solutions for the commercial market, government healthcare plans, and property and casualty healthcare payors. It operates in the Industrials sector.

Claritev Corporation (CTEV) appears to be a good buy right now. The current price is $23.50, which is significantly lower than the average analyst price target of $40, indicating a potential upside of over 70%. Additionally, the company has shown a positive trend with a 6.24% increase over the past five days and a narrowed quarterly loss of $59.23 million, down from $62.64 million year-over-year, reflecting improved operational efficiency. However, a key risk is the high debt-to-equity ratio, which stands at 0%, indicating potential financial instability if market conditions worsen.

暂无帖子

注册或登录后参与讨论

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易